Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A number of therapeutic strategies for treating Alzheimer's disease have focused on reducing amyloid burden in the brain. Among these approaches, the expression of amyloid β peptide (Aβ)‐degrading enzymes in the brain has been shown to be effective but to date not practical for treating patients. We report here a novel strategy for lowering amyloid burden in the brain by peripherally expressing the Aβ‐degrading enzyme neprilysin on leukocytes in the 3xTg‐AD mouse model of Alzheimer's disease. Through transplantation of lentivirus‐transduced bone marrow cells, the Aβ‐degrading protease neprilysin was expressed on the surface of leukocytes. This peripheral neprilysin reduced soluble brain Aβ peptide levels by ∼30% and lowered the accumulation of amyloid β peptides by 50–60% when transplantation was performed at both young and early adult age. In addition, peripheral neprilysin expression reduced amyloid‐dependent performance deficits as measured by the Morris water maze. Unlike other methods designed to lower Aβ levels in blood, which cause a net increase in peptide, neprilysin expression results in the catabolism of Aβ to small, innocuous peptide fragments. These findings demonstrate that peripherally expressed neprilysin, and likely other Aβ‐degrading enzymes, has the potential to be utilized as a therapeutic approach to prevent and treat Alzheimer's disease and suggest that this approach should be explored further. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 2×
“Lentivirus constructs were prepared as previously described (Marr et al., 2003), with virus produced in HEK293FT cells (Invitrogen, Carlsbad, CA) using a four-plasmid transfection system (Dull et al., 1998; Miyoshi et al., 1998).”
MethodImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“…with synthetic Ab (Schenk et al., 1999; Janus et al., 2000; Morgan et al., 2000; Weiner et al., 2000; Das et al., 2001) or passive administration of anti-Ab antibodies (Bard et al., 2000; DeMattos et al., 2001, 2002) reduced behavioral impairment and plaque formation in mouse models of AD.”
BackgroundRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431 · cited 1×
“Immunizing with synthetic Ab (Schenk et al., 1999; Janus et al., 2000; Morgan et al., 2000; Weiner et al., 2000; Das et al., 2001) or passive administration of anti-Ab antibodies (Bard et al., 2000; DeMattos et al., 2001, 2002) reduced behavioral impairment and plaque formation in mouse models of…”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 2×
“This would result in a decrease in peripheral vascular resistance and an increase in blood pressure (Shibata et al., 2000; Weber, 2001).”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 3×
“An alteration of peripheral/brain Ab dynamics represents a therapeutic target of Alzheimer’s disease, as suggested by other studies (DeMattos et al., 2001, 2002; Matsuoka et al., 2003).”
BackgroundInfluentialDevelopment of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196 · cited 1×
“Lentivirus constructs were prepared as previously described (Marr et al., 2003), with virus produced in HEK293FT cells (Invitrogen, Carlsbad, CA) using a four-plasmid transfection system (Dull et al., 1998; Miyoshi et al., 1998).”
MethodAmyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 2×
“To test the effect of peripheral expression, NEP and an inactive NEP mutant (NEPx) were expressed on hematopoietic cells, and their effect on brain Ab burden was determined in the 3xTg-AD (Oddo et al., 2003a,b) mouse model of AD.”
BackgroundSelf-citationAβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637 · cited 3×
“Ab9 (anti-Ab1–16) was used as the capture antibody and 4G8 (anti-Ab17–24) as the detection antibody for total Ab analysis.”
BackgroundMethodInfluentialSelf-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563
Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease
Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379 · cited 1×
“There was no significant thioflavin S-positive plaque formation in any group, consistent with the report that in these mice thioflavin S-positive plaques are not significant at this age (Oddo et al., 2006).”
BackgroundSelf-citationRacke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
Lentiviral vectors for enhanced gene expression in human hematopoietic cells
Ramezani, A., Hawley, T. S., & Hawley, R. G. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0190 · Cited by 217 · cited 2×
“decline in NEP expression could be due to the induction of antibody against NEP, although we failed to detect such antibodies by ELISA, or might have resulted from a decrease in cytomegalovirus (CMV) immediate early promoter activity (Scharfmann et al., 1991; Kay et al., 1992; Ramezani et al., 2000).”
Background
Cited by
Xiang, Y., Bu, X.-L., Liu, Y.-H., Zhu, C., Shen, L.-L., Jiao, S.-S., Zhu, X.-Y., Giunta, B., Tan, J., Song, W.-H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1477-1 · Cited by 277
Self-citationAβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
“So too did transplantation of NEP-expressing leukocytes into 3 Tg AD mice, which had lower levels of soluble (30%) and plaque-associated AA (50%Y60%) and improved cognitive performance (254).”
BackgroundAre amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
Spines, plasticity, and cognition in Alzheimer's model mice
Spires-Jones, T., & Knafo, S. (2012) · Neural Plasticity · doi:10.1155/2012/319836 · Cited by 133
Clearance of Amyloid-Beta in Alzheimer’s Disease: Shifting the Action Site from Center to Periphery
Liu, Y.-H., Wang, Y.-R., Xiang, Y., Zhou, H.-D., Giunta, B., Mañucat-Tan, N. B., Tan, J., Zhou, X.-F., & Wang, Y.-J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8694-9 · Cited by 99
Self-citation
Metadata
- Authors
- Guan, H., Liu, Y., Daily, A., Police, S., Kim, M., Oddo, S., LaFerla, F. M., Pauly, J. R., Murphy, M. P., & Hersh, L. B.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2008-11-19
- Volume
- 87
- Issue
- 6
- Pages
- 1462-1473
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2073991180
- Cited by
- 81
- References
- 15
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.